Elena Garralda MD PhD is a Medical Oncologist and a Clinical Investigator. She serves as Director of the Molecular Cancer Therapy Research Unit (UITM) and as Codirector of the Clinical Research Program at VHIO. She coordinates complex clinical trials with drugs in early development focused on targeted agents and immunotherapies. Her work specially emphasizes immuno-oncology and first-in-human studies of targeted therapies, rational combinations, and biomarker-driven trials. She actively integrates genomic profiling and immunological insights to guide biomarker-driven treatment strategies, and she is recognized for pioneering the implementation of next-generation cell therapies, including tumor-infiltrating lymphocytes (TILs) targeting neo-antigens in tumors resistant to checkpoint inhibitors.
